Karyopharm Shares Slump on Retention Plan Amid Market Volatility

Karyopharm Therapeutics saw its stock slide to $7.50 after-hours as the company revealed a new cash incentive scheme for its top leadership. The move sparked immediate investor concern, driving shares down significantly despite the broader context of active trading across the biotech and technology sectors.

Elsewhere, MKDWELL signaled a major expansion by agreeing to acquire Landvision Technology, the parent firm behind various smart-home and IoT products. The $240 million deal buoyed investor sentiment, pushing the stock up 6% to $11.83. Meanwhile, Advanced Biomed experienced a sharp 35% surge to $6.80 after abandoning a $25 million share issuance agreement, a decision that investors interpreted as a positive shift for the company's equity position.